TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05736029: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics

Sponsor: OncoHost Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 350 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT05736029 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05736029 Rescue Dossier →